Four proteins in the kidneys likely contribute to the development of ANCA-associated vasculitis (AAV), and may be used as diagnostic markers and targets of potential therapies, a study found. The proteins — PDK4, PPARGC1A, FN1, and PSMB10 — are “novel biomarkers that may refine our understanding and management of AAV,”…
News
A greater disease burden and poorer physical quality of life were found for people with eosinophilic granulomatosis with polyangiitis (EGPA) who test positive for self-reactive anti-neutrophil cytoplasmic antibodies (ANCAs) against the myeloperoxidase (MPO) protein compared with EGPA patients who don’t have such autoantibodies. Those are the findings of a new…
Treatment with Tavneos (avacopan) appeared to more effectively suppress organ damage — while also significantly lowering glucocorticoid dosages and associated adverse events — in people with ANCA-associated vasculitis (AAV), according to a real-world study in Japan. The study looked at the safety and effectiveness of glucocorticoids plus rituximab…
In ANCA-associated vasculitis (AAV), about 1 in every 4 patients with glomerulonephritis, a type of kidney inflammation, have C3 immune protein deposits in their kidneys, and these are linked to more severe kidney problems, a study shows. These deposits didn’t appear to interfere with how long patients lived or…
Preliminary data from a Phase 1 clinical trial testing NKX019, Nkarta’s cell therapy candidate for ANCA-associated vasculitis (AAV) and other autoimmune conditions, are expected in the second half of this year. That’s according to a mid-year update from the biotechnology company, which is developing the natural killer (NK) cell…
A low-dose course of glucocorticoid therapy results in similar outcomes as a higher-dose option in people with ANCA-associated vasculitis (AAV) and kidney involvement, though it may lower risk of serious infection, a study reports. “Our findings reinforce the safety and efficacy of reduced [glucocorticoid] as the initial [glucocorticoid] regimen…
Use of the experimental therapy BDB-001 helps adults with ANCA-associated vasculitis (AAV) achieve at least partial disease remission, while reducing the need for standard glucocorticoids. That’s according to new data from a Phase 1/2 clinical trial conducted in China. Glucocorticoids, also commonly called corticosteroids, are a standard AAV…
Combining two diagnostic systems used to classify cases of ANCA-associated vasculitis (AAV) in adults improved classification performance in a pediatric AAV patient population, according to a study in China. Identifying types of AAV is important to ensure effective clinical care in children, researchers noted. “Considering that distinct clinical…
Alivedx’s Mosaiq Aiplex vasculitis assay, a platform test for the two main self-reactive antibodies that drive most cases of ANCA-associated vasculitis (AAV), is now available for clinical use in the European Union (EU). The test is also able to detect self-reactive antibodies linked to another autoimmune condition marked…
Measuring circulating microRNAs — short RNA molecules that ultimately suppress gene activity — could offer doctors a less invasive way to monitor glomerulonephritis, a type of kidney inflammation, in ANCA-associated vasculitis (AAV), a study found. However, the study included a small number of patients, and testing microRNAs, or miRNAs,…
Recent Posts
- Finding a little light on dark winter days is key with ANCA vasculitis
- Real-world data show high AAV remission rates with Tavneos
- GPA and EGPA overlap features linked to disease severity, survival risk: Study
- Starting a new year with ANCA vasculitis
- New analysis identifies phase-specific relapse risks in AAV treatment